These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 22112482)
1. Early events during neoplastic progression in Barrett's esophagus. Reid BJ Cancer Biomark; 2010; 9(1-6):307-24. PubMed ID: 22112482 [TBL] [Abstract][Full Text] [Related]
2. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379 [TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316 [TBL] [Abstract][Full Text] [Related]
4. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291 [TBL] [Abstract][Full Text] [Related]
5. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Whitson MJ; Falk GW Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196 [TBL] [Abstract][Full Text] [Related]
6. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402 [TBL] [Abstract][Full Text] [Related]
7. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Kaz AM; Grady WM; Stachler MD; Bass AJ Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206 [TBL] [Abstract][Full Text] [Related]
8. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus]. Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323 [TBL] [Abstract][Full Text] [Related]
9. The diagnosis and management of Barrett's esophagus. DeMeester SR; DeMeester TR Adv Surg; 1999; 33():29-68. PubMed ID: 10572561 [TBL] [Abstract][Full Text] [Related]
10. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Maslyonkina KS; Konyukova AK; Alexeeva DY; Sinelnikov MY; Mikhaleva LM Cancer Med; 2022 Jan; 11(2):447-478. PubMed ID: 34870375 [TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Beilstein M; Silberg D Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613 [TBL] [Abstract][Full Text] [Related]